Crown Bioscience Snapshot
Our Mission: Our mission is to empower our customers to improve human health.
We do this by engaging the finest scientific talent, upholding the highest quality standards, and relentlessly pursuing innovation.
Every day we strive to accelerate and de-risk drug development to help realize a world where every patient gets the right treatment, at the right time.
Our Vision: Together we can realize a world where every patient gets the right treatment, at the right time.
We do this by engaging the finest scientific talent, upholding the highest quality standards, and relentlessly pursuing innovation.
Every day we strive to accelerate and de-risk drug development to help realize a world where every patient gets the right treatment, at the right time.
Our Vision: Together we can realize a world where every patient gets the right treatment, at the right time.
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing discovery, preclinical, and translational platforms to advance oncology and immuno-oncology.
Known for their high quality and expansive in vivo, in vitro and ex vivo preclinical models, they partner with their clients to quantify the efficacy and pharmacological profile of their drug candidate before they move into the clinic.
The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Additionally, further services available in the areas of high content imaging and a 3D Ex Vivo Patient Tissue Platform, provide greater insights into complex disease pathophysiology. A range of biomarker analysis and applied genomics services are also available to optimize therapeutic benefit.
Crown Bioscience helps to deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has 13 facilities in the US, Europe, and APAC. Find out more: www.crownbio.com
Known for their high quality and expansive in vivo, in vitro and ex vivo preclinical models, they partner with their clients to quantify the efficacy and pharmacological profile of their drug candidate before they move into the clinic.
The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Additionally, further services available in the areas of high content imaging and a 3D Ex Vivo Patient Tissue Platform, provide greater insights into complex disease pathophysiology. A range of biomarker analysis and applied genomics services are also available to optimize therapeutic benefit.
Crown Bioscience helps to deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has 13 facilities in the US, Europe, and APAC. Find out more: www.crownbio.com
